LAB
STANDARD BIOTOOLS INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Viking Global Investors | Q2 2024 | 8Q | $2.53 | $0.99 | -61% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $1.55 | $0.99 | -36% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $1.55 | $0.99 | -36% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $1.55 | $0.99 | -36% |
| Point72 Asset Management | Q1 2026(8Q snapshot) | 1Q | $1.12 | $0.99 | -12% |
| D.E. Shaw | Q2 2026(8Q snapshot) | 1Q | $0.98 | $0.99 | +1% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments | Q3 2024 | Q2 2025 | → $1.05 | -32% |
| Renaissance Technologies | Q3 2024 | Q1 2025 | → $1.33 | -18% |
| Glenview Capital | Q4 2020 | Q2 2021 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at STANDARD BIOTOOLS INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 22, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-237189May 22, 2026
- Form 40001193125-26-237182May 22, 2026
- Form 40001193125-26-237181May 22, 2026
- Form 40001193125-26-148615Apr 8, 2026
- Form 40001193125-26-148614Apr 8, 2026
- Form 40001193125-26-148613Apr 8, 2026
- Form 40001193125-26-086197Mar 2, 2026
- Form 40001193125-26-086158Mar 2, 2026
- Form 40001193125-26-086154Mar 2, 2026
- Form 40001193125-26-067641Feb 24, 2026
- Form 40001193125-26-067638Feb 24, 2026
- Form 40001193125-26-067636Feb 24, 2026
- Form 40000919574-25-007243Dec 4, 2025
- Form 40000919574-25-007187Nov 26, 2025
- Form 40001193125-25-293843Nov 24, 2025
Fundamentals
XBRL · STANDARD BIOTOOLS INC.Annual figures sourced directly from STANDARD BIOTOOLS INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for STANDARD BIOTOOLS INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KJun 8, 2026
- 8-KMaterial eventJun 5, 2026
- 8-KMaterial eventJun 3, 2026
- 8-KMaterial eventMay 28, 2026
- 10-QQuarterly reportMay 6, 2026
- 8-KMaterial eventMay 5, 2026
- DEF 14AProxy statementApr 27, 2026
- 8-KMaterial eventApr 24, 2026
- 10-KAnnual reportMar 16, 2026
- 8-KMaterial eventFeb 24, 2026
- 8-K/AFORM 8-K/AFeb 5, 2026
- 8-KFORM 8-KJan 30, 2026
- 8-KMaterial eventJan 8, 2026
- 10-QQuarterly reportNov 4, 2025
- 8-KMaterial eventNov 4, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| D.E. Shaw | Q2 2026 | open | $0.98 | $0.99 | +1% |
| Point72 Asset Management | Q1 2026 | open | $1.12 | $0.99 | -12% |
| Citadel Advisors | Q3 2025 | open | $1.22 | $0.99 | -19% |
| Citadel Advisors | Q3 2024 | Q2 2025 | $1.55 | $1.05 | -32% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | $1.55 | $1.05 | -32% |
| AQR Capital Management | Q3 2024 | open | $1.55 | $0.99 | -36% |
| Millennium Management | Q3 2024 | open | $1.55 | $0.99 | -36% |
| Renaissance Technologies | Q3 2024 | Q1 2025 | $1.62 | $1.33 | -18% |
| Viking Global Investors | Q2 2024 | open | $2.53 | $1.16 | -54% |
| Glenview Capital | Q4 2020 | Q2 2021 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.